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Summary
Familial porphyria cutanea tarda (f-PCT) results from
the half-normal activity of uroporphyrinogen decarbox-
ylase (URO-D). Heterozygotes for this autosomal dom-
inant trait are predisposed to photosensitive cutaneous
lesions by various ecogenic factors, including iron over-
load and alcohol abuse. The 3.6-kb URO-D gene was
completely sequenced, and a long-range PCR method
was developed to amplify the entire gene for mutation
analysis. Four missense mutations (M165R, L195F,
N304K, and R332H), a microinsertion (g10insA), a de-
letion (g645D1053), and a novel exonic splicing defect
(E314E) were identified. Expression of the L195F,
N304K, and R332H polypeptides revealed significant
residual activity, whereas reverse transcription–PCRand
sequencing demonstrated that the E314E lesion caused
abnormal splicing and exon 9 skipping. Haplotyping
indicated that three of the four families with the g10insA
mutation were unrelated, indicating that these microin-
sertions resulted from independent mutational events.
Screening of nine f-PCT probands revealed that 44%
were heterozygous or homozygous for the common
hemochromatosis mutations, which suggests that iron
overload may predispose to clinical expression. How-
ever, there was no clear correlation between f-PCT dis-
ease severity and the URO-D and/or hemochromatosis
genotypes. These studies doubled the number of known
f-PCT mutations, demonstrated that marked genetic
heterogeneity underlies f-PCT, and permitted presymp-
tomatic molecular diagnosis and counseling in these
families to enable family members to avoid disease-pre-
cipitating factors.
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Introduction
Familial porphyria cutanea tarda (f-PCT; MIM 176100)
is an autosomal dominant disorder that results from the
systemic half-normal activity of uroporphyrinogen de-
carboxylase (URO-D; E.C.4.1.1.37), the fifth enzyme in
the heme biosynthetic pathway (Kushner et al. 1976; de
Verneuil et al. 1978). The enzymatic defect leads to the
accumulation of uroporphyrins and predisposes gene
carriers to cutaneous manifestations including photo-
sensitive dermatitis, mechanical fragility of the light-
exposed skin, hyperpigmentation, and hypertrichosis
(Grossman et al. 1979; Kappas et al. 1995; McGovern
et al. 1996; Elder 1998). Homozygosity for URO-Dmu-
tations results in the rarer but more severe homozygous
dominant disorder hepatoerythropoietic porphyria
(HEP), which has clinical onset in childhood and a phe-
notype similar to that of congenital erythropoietic por-
phyria (Smith 1986; Koszo et al. 1990; Kappas et al.
1995). In addition, a more common acquired form, spo-
radic porphria cutanea tarda (s-PCT), is characterized
by similar clinical features but is due to the isolated
deficiency of hepatic URO-D activity (de Verneuil et al.
1978; Elder et al. 1978). The liver-specific enzyme de-
ficiency in s-PCT does not result from mutations in the
URO-D gene (Garey et al. 1993) but is induced by un-
known mechanisms associated with iron overload, al-
cohol abuse, estrogens, and/or hepatitis C infection
(Grossman et al. 1979; Fargion et al. 1992; DeCastro
et al. 1993; Kappas et al. 1995).
URO-D catalyzes the conversion of uroporphyrinogen
III to coproporphyrinogen III by the sequential removal
of the four carboxylic groups of the acetic-acid side
(Jackson et al. 1976; de Verneuil et al. 1980). The en-
zyme has been purified to homogeneity from human
erythrocytes and has been shown to have a molecular
weight of ∼46 kD (de Verneuil et al. 1983). Recently,
the crystal structure of human URO-D has been deter-
mined at 1.6-A˚ resolution (Whitby et al. 1998), which
has revealed a homodimeric structure with a single active
site. The enzyme is encoded by a single gene localized
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to chromosomal region 1p34 (de Verneuil et al. 1984;
Dubart et al. 1986). The URO-D cDNA was isolated in
1986 and contains an open reading frame of 1,104 nu-
cleotides that encodes a 367-amino-acid polypeptide
(Romeo et al. 1986). Portions of the genomic sequence
have been reported (Romana et al. 1987; McManus et
al. 1994), but only recently, while this researchwas being
performed, was the entire 3-kb gene sequenced (Moran-
Jimenez et al. 1996; Sorkin et al. 1996). The gene con-
tains 10 exons and a TATA box and a GC box in the
promoter region. There is no evidence for erythroid-spe-
cific and housekeeping forms of URO-D, as have been
identified in porphobilinogen synthase and hydroxy-
methylbilane synthase (Grandchamp et al. 1987; Yoo et
al. 1993; Kaya et al. 1994). The availability of the cDNA
and genomic sequences encoding URO-D permits in-
vestigation of the mutations causing f-PCT. Such studies
are particularly valuable for accurate presymptomatic
diagnosis and counseling of gene carriers in f-PCT fam-
ilies. To date, only eight mutations, (L253Q, G281V,
G281E, G318R, I334T, 828D31, 890DC, and IVS61)
have been identified in unrelated families with f-PCT
(Garey et al. 1989, 1990; Roberts et al. 1995; McManus
et al. 1996; also see Human Gene Mutation Database).
Although iron overload has been considered an im-
portant precipitating factor for s-PCT (Lundvall et al.
1970; Felsher and Kushner 1977), its role in f-PCT is
not clear. The recent identification of the hemochro-
matosis (HFE) gene and its common C282Y and H63D
mutations has permitted investigation of the frequency
of these lesions in PCT patients (Feder et al. 1996). To
date, the occurrence of these HFE mutations in f-PCT
has not been investigated, but in the two European s-
PCT populations studied to date, the frequency of either
the C282Y or H63D mutation was increased in British
and Italian s-PCT patients compared with that in the
respective normal populations (Fargion et al. 1996; Rob-
erts et al. 1997; Santos et al. 1997; Sampietro et al.
1998). The frequency of the C282Y allele in 41 British
s-PCT patients was almost fivefold higher (30.5% vs.
5.9%) than that in normal British individuals, whereas
there was no difference between the frequency of the
H63D allele in the British s-PCT and that in normal
British individuals (Roberts et al. 1997). Interestingly,
the H63D allele was twofold more frequent (28.7% vs.
12.6%) in the 68 Italian s-PCT patients than in normal
Italian individuals, whereas there was no difference be-
tween the frequency of the C282Y allele among Italian
s-PCT patients and normal Italian individuals (Sampie-
tro et al. 1998). In sum, the occurrence of heterozygosity
or homozygosity for the HFE mutations among British
and Italian s-PCT patients was 68.3% and 52.9%, re-
spectively—frequencies higher than those in the respec-
tive normal populations.
In the present report, we describe an efficient long-
range PCR method for amplifying the entire 3.6-kb
genomic sequence as a single amplicon for detection
of gene rearrangements and for sequencing. By this
method, seven new URO-D mutations, including four
missense mutations, a single base insertion, a deletion,
and a novel splicing defect, were identified in 10 unre-
lated f-PCT patients from Argentina. Each missense mu-
tation was characterized by expression studies, and the
splice-site mutation was confirmed by reverse transcrip-
tion–PCR (RT-PCR) analysis. Of interest, the microin-
sertion found in four presumably unrelated f-PCT fam-
ilies was shown by haplotype analysis to have arisen
independently in at least three of the families. In addi-
tion, the occurrence of HFE C282Y and H63D muta-
tions was determined in these probands with the inher-
ited form of PCT, to assess their predisposition to iron
overload and to correlate disease severity with their
URO-D and HFE genotypes.
Material and Methods
Patient Specimens, Enzyme Assays, and DNA Isolation
Ten unrelated f-PCT patients from Argentina were
studied. Fresh 24-h urine samples and peripheral blood
samples were collected from each f-PCT patient and fam-
ily member, for diagnostic and research purposes, after
informed consent had been obtained, and the urinary
porphyrin concentrations (Batlle 1997) and the eryth-
rocyte URO-D activity of each patient were determined
(Lim et al. 1983; Afonso et al. 1985). Cultured lymphoid
cell lines were established and maintained as described
elsewhere (Anderson and Gusella 1984). DNA was iso-
lated from either peripheral blood or cultured lympho-
blasts by the Puregene DNA Isolation Kit (Gentra
Systems).
PCR Amplification of the Entire URO-D Gene
PCR primers for amplifying the introns of the URO-
D gene were designed on the basis of the cDNA and
intron-exon sequences (Romana et al. 1987; McManus
et al. 1994; Moran-Jimenez et al. 1996), and the entire
genomic sequence was determined. Here, the A of the
initiation of translation ATG is numbered as 1; upstream
nucleotides are indicated by negative numbers, begin-
ning with C as1. PCR and sequencing were performed
as described elsewhere (Chen et al. 1994). On the basis
of the information obtained from sequencing the entire
gene, primers for long-range PCR and the sequencing of
each exon and intron/exon boundaries were designed as
shown in table 1.
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Table 1
PCR Primers for Long-Range Amplification, Sequencing Reactions, and Site-Directed
Mutagenesis of the URO-D Gene
Primer Type Sequence
Long-range PCR:
Upper 5′-TATGGACCTGGCTGGATAAGACTGTTGGT-3′
Lower 5′-GGGACAATCTTTCACAAACAAAACTACAC-3′
Sequencing, for each exon:
1 5′-TACAGAAAGGGGCGGAGCCTGGACTGG-3′
2 5′-GGGAGCTGGCCTGGAGGAGGTAGATAG-3′
3 5′-GAGGAGAAAAGTTTTCGAGGGGCA-3′
4 5′-CAAAAGAGGGAAAGATTTATGCCTTCA-3′
5 5′-CTGAACAGAACCTTTCCTCCTGGATTC-3′
6 5′-GGGGTAGACAAAAGGAAGGGTCAGTC-3′
7 5′-GTGGATTTTGTATGTGGGGGAAACTTC-3′
8 5′-GGGATGGGTTGAGTGAAGGTGGTCCTG-3′
9 5′-GGAGCTGCCATGTATGCAGTTACCA-3′
10 5′-ATAGGGAGGACAAAGGCTTGCTGGT-3′
Site-directed mutagenesis:
R332H-S 5′-CTGTGCCTTGTATGCATCTGAGGAGGAGATCGGGCAGTTGGTGAAGC-
AGATGCTGGATGACTTTGGACCACATCACTAC-3′
R332H-AS 5′-ATCAGGCTGAAAATCTTCTCTCATCCGCCA-3′
N304K-S 5′-TGGCCAAGCAAGTGAAGGCCAGGTTGCGGGA-3′
N304K-AS 5′-TGCCCGATCTCCTCCTCAGATGCATACAAGGCACAGGGGTCCAGTTTGCC-3′
M165R-1 5′-TGTTGTACCCCAGGCACTGGGCATGGAGGT-3′
M165R-2 5′-CACCACCCTCAACCCTGTATGTCATCAGG-3′
M165R-3 5′-CCTGATGACATACAGGGTTGAGGGTGGTG-3′
M165R-4 5′-ATCAGGCTGAAAATCTTCTCTCATCCGCCA-3′
L195F-1 5′-TGTTGTACCCCAGGCACTGGGCATGGAGGT-3′
L195F-2 5′-CAGAGCATCAGTGAAGATGCGAAGCAGCT-3′
L195F-3 5′-AGCTGCTTCGCATCTTCACTGATGCTCTG-3′
L195F-4 5′-ATCAGGCTGAAAATCTTCTCTCATCCGCCA-3′
RT-PCR:
RT-1 5′-GTTACAGACAGCTGACCATGGA-3′
RT-2 5′-CGATCAATCATCTGTGTTAGTGG-3′
Long-Range PCR and Cyclic Sequencing
The URO-D gene was amplified from genomic DNA
(1 mg) in a single reaction using sense and antisense prim-
ers (table 1) and the GeneAmp XL PCR Kit (Perkin-
Elmer), according to the manufacturer’s instructions.
For the first 16 cycles, annealing and extension were for
3 min each at 67C, and for the last 12 cycles the times
were increased 15 s each cycle, with a final extension
cycle of 10 min at 72C. A portion of the PCR product
was analyzed by agarose-gel electrophoresis to deter-
mine that the long-range reaction was successful and to
identify any gross gene rearrangements. For sequencing,
each exon and the adjacent intron/exon boundary was
PCR-cycle sequenced with the indicated primers (table
1), with 1 ml of the long-range PCR product used as the
template and with the AmpliCycle Sequencing Kit (Per-
kin-Elmer) used according to manufacturer’s instruc-
tions. The PCR sequencing program consisted of 30 cy-
cles of 95C for 30 s, 60C for 30 s, and 72C for 1
min. The reactions were run on acrylamide sequencing
gels. The gels were dried, placed against Kodak X-OAR
film for 24 h, and then developed.
Prokaryotic Expression and Characterization of URO-D
Point Mutations
The normal and mutant URO-D alleles were ex-
pressed in Escherichia coli strain lJM109, by the
pKK223-3 expression system (Pharmacia Biotechology)
as described elsewhere (Tsai et al. 1988; Warner et al.
1992; Chen et al. 1994; Xu et al. 1995). The EcoRI
fragment of the full-length URO-D cDNA was blunt-
end ligated into the HindIII site of pKK223-3. This con-
struct was designated “pK-UROD.” Each of the mis-
sense mutations was introduced into the pK-URODplas-
mid by site-directed mutagenesis (Chen et al. 1994). For
the R332H and N304K mutations, each expression con-
struct was generated by amplification with the indicated
sense and antisense primers (table 1). To introduce mu-
tations M165R and L195F into the expression vector,
two amplifications were necessary, since there were no
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convenient restriction sites. First, each region containing
a restriction site was amplified individually, and then the
PCR products were ligated. ForM165R, one set of prim-
ers was pM165R-1 and pM165R-2, whereas the other
primer set was pM165R-3 and pM165R-4. After the
two PCR products had been ligated together, the final
construct was produced by primers 1 and 4. A similar
procedure was used to construct an expression vector
containing the L195F mutation. One primer set was
pL195F-1 and pL195F-2, whereas the other set was
pL195-3 and pL195-4. Primers 1 and 4 also were used
to produce the final L195F construction. Each expres-
sion construct was sequenced, to ensure that only the
desired mutation had been introduced and that the re-
mainder of the sequence was correct.
Assay of URO-D Activity
Transfection, bacterial growth, and isopropylthioga-
lactoside (IPTG) induction were as described elsewhere
(Tsai et al. 1988). The cells were washed twice with PBS,
and the pellet was resuspended in 250 ml of lysis buffer
(0.067 M sodium phosphate, pH 7.0, 0.1% Triton-X-
100) and sonicated on ice. The extract was then centri-
fuged for 1 min at 13,000 g, and the supernatant was
used as the enzyme source. The URO-D assay consisted
of 0.67 M sodium phosphate, pH 7.0 (50 ml), 20 mM
glutathione (50 ml), 1 mM EDTA (50 ml), uroporphyrin-
ogen III (35 mg/ml; 50 ml), obtained by uroporphyrin
reduction in 25 mM NaOH with 3% sodium amalgam,
H2O (250 ml), and bacterial extract (50 ml). The reaction
was performed in tubes that had been filledwith nitrogen
gas and were incubated for 30 min at 37C, with shak-
ing, in the dark. The reaction was stopped by the ad-
dition of 55 ml of 50% trichloroacetic acid. The porphy-
rinogens were oxidized to porphyrins by exposure to
white light for 20 min. The samples were then centri-
fuged for 1 min at 13,000 g, filtered through 0.2-mm
Whatman filters, and analyzed by high-pressure liquid
chromotagraphy (HPLC), according to the method of
Lim et al. (1983). Specific activity was calculated as nmol
of coproporphyrin III produced/h/mg protein. The na-
nomoles of coproporphyrin III were determined by ex-
trapolation from a calibration curve of nanomoles of
coproporphyrin III versus peak area.
Thermal Stability of pK-URO-D and pK-R332H
Bacterial lysates containing either pK-UROD or pK-
UROD-R332H were induced with IPTG for 3 h. Ex-
tracts were diluted with 0.067M sodium phosphate buf-
fer, pH 7, to the same protein concentration (0.1–0.2
mg/ml). They were preincubated for various times, from
0 to 180 min, at 37C, were placed on ice, and then
were assayed for URO-D activity. Two enzyme prepa-
rations from independent inductions were assayed, and
the results were averaged.
RT-PCR Studies of URO-D Mutation E314E
To confirm that mutation E314E was a splice-site mu-
tation, RT-PCR was performed. Leukocytes were iso-
lated from blood by Ficoll-Paque (Pharmacia Biotech),
and RNA was isolated from the leukocytes by RNA Zol
B (Tel-Test) and was reverse transcribed with M-MLV
Reverse Transcriptase and Oligo(dT)12–18 primers (Life
Technologies), according to manufacturer’s instructions.
The total amount of cDNA was then amplified by prim-
ers RT-1 and RT-2 (table 1), and the PCR product was
analyzed on 1.5% agarose gels. Each band was cut out
of the gel separately, and the DNAwas eluted by soaking
the agarose in a small amount of Tris-EDTA buffer (10
mM Tris, 1 mM EDTA, pH 7.4). Each exon was then
cycle sequenced by the fmol DNA cycle sequencing kit
(Promega), according to manufacturer’s instructions.
Analysis of the HFE C282Y and H63D Mutations
Genomic DNAs from the f-PCT probands were an-
alyzed for the common HFE mutations, C282Y and
H63D. DNA was PCR amplified by the primers and
conditions described by Feder et al. (1996). The PCR
products were cut by the restriction enzyme Sau3AI
(New England Biolabs), in the case of H63D, and the
restriction enzyme RsaI, in the case of C282Y, and were
analyzed by agarose-gel electrophoresis.
Haplotyping of f-PCT Probands with URO-D Mutation
g10insA
To determine whether the four presumably unrelated
probands from Argentina who had the g10insA muta-
tion were related to each other, haplotyping was per-
formed. Six CA-repeat markers from the chromosome
1p34 region (Dib et al. 1996) were obtained from Re-
search Genetics; these six markers, from centromere
to telomere, were D1S193 (AFM057xf4), D1S463
(AFM154xg11), D1S2713 (AFMa349yb5), D1S211
(AFM122xe1), D1S2724 (AFMb015wc9), and D1S451
(AFM248tf9). PCR amplification and gel analysis were
performed as described by Gelb et al. (1995).
Results
Sequencing of the URO-D Gene
To facilitate identification of mutations in the URO-
D gene, the entire genomic sequence was determined by
primers based on the published cDNA and intron/exon
boundary sequences (Romeo et al. 1986; Romana et
al. 1987). Our sequence (Entrez Nucleotide Sequence
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Table 2
Sequence Differences Identified in the URO-D Gene
Location and
Genomic Numbera Differenceb
5′ UTR:
225 insG
222 delT
207 insC
213 TrG
172 insC
167 insG
158 insC
Intron 1:
120 delA
146 insG
236 TrC
237 CrT
317 delT
322 delG
474 insCACC
543 delG
593 delG
598 ArG
Intron 2:
794 insG
Intron 6:
1853 CrA
1855 GrC
1901 TrC
Intron 9:
2768 delC
2790 delC
2848 CrA
2849 ArC
2858 CrA
2941 insG
2976 delT
2990 delC
3001 CrG
3003 insC
3’ UTR:
3234 CrG
3235 CrT
3311 DelC
a Based on sequence in present study.
b Based on comparison of sequence in present study
(Entrez Nucleotide Sequence Search, Genbank acces-
sion number AF047383) versus that reported by
Moran-Jimenez et al. (1996).
Figure 1 Agarose-gel electrophoresis of 3.6-kb URO-D long-
range PCR product amplified from genomic DNA of a normal indi-
vidual. The PCR product was electrophoresed in 1% agarose with
Tris-Borate-EDTA buffer, pH 8.4. The DNA size marker is the lambda
DNA-HindIII digest (New England Biolabs).
Search, Genbank accession number AF047383) was
3,659 bp long, including both 330 bp 5′ upstream from
the initiation of translation ATG and 96 bp of flanking
sequence 3′ of exon 10. During our studies, the genomic
structure of URO-D gene was published (Moran-Jime-
nez et al. 1996). Our exonic sequences were similar to
the published genomic sequence, except for a 1-base dif-
ference in exon 4, a C at position g1043 in place of a
T, changing codon 77 from CTT to CCT, which encoded
a leucine-to-proline substitution. This was consistent
with the previously published cDNA sequence (Romeo
et al. 1986). Compared with the originally published
cDNA sequence (Romeo et al. 1986), our genomic se-
quence had the five base changes previously noted by
other investigators (McManus et al. 1994; Moran-Ji-
menez et al. 1996), in cDNA codons 23 (GCTrGCC),
305 (TTGrCTG), and 337 (TTGrCTG); these DNA
changes did not alter the amino acid sequence. However,
DNA changes at codons 103 (AGCrGGC) and 120
(GCGrCGC) did alter the amino acid sequence. In ad-
dition, 34 differences between the previously published
(Moran-Jimenez et al. 1996) sequence and our sequence
were identified, including insertions, deletions, and base
changes (table 2). Our sequence was observed in the
homozygous state in amplified genomic DNAs from nor-
mal individuals and in the normal alleles of the f-PCT
patients studied. In addition, heterozygosity for an in-
tron 6 polymorphism, g1835GrT, was identified in all
10 Argentinian f-PCT probands and in 1 of the 15 nor-
mal Argentinean individuals.
Identification of Mutations by Long-Range PCR and
Cyclic Sequencing
On the basis of the URO-D genomic sequence, primers
were designed to amplify the entire 3.6-kb gene as a
single PCR product. Each exon was then cycle se-
quenced, with the long-range PCR product used as the
template (fig. 1). By this method, the URO-D gene was
amplified and sequenced from 10 Argentinean f-PCT
probands whose biochemical diagnosis was based on
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Table 3
Biochemical and Molecular Findings in Argentinean f-PCT Probands
Source (Ancestry/Sex)
of Proband
Total Urinary
Porphyrins
(mg/24 h)
Plasma
Porphyrin
Index
URO-D
Erythrocyte
Activity
(% of Normala) URO-D Mutation
Normal controls !250 !1.3 100 )
1 (Italian/F) 8,910 7.48 45 E314E
2 (Portuguese/M) 11,600 6.00 42 R332H
3 (Spanish/F) 3,040 3.10 50 L195F
4 (Italian/F) 5,010 6.75 46 M165R
5 (Spanish/F) 1,130 2.30 51 N304K
6 (Spanish/M) 2,030 2.10 42 g645D1053
7 (Arabic/F) 7,530 5.87 52 g10insA
8 (Spanish/M) 4,490 4.30 40 g10insA
9 (Spanish/M) 3,120 3.43 44 g10insA
10 (Spanish/M) 3,960 4.25 22 g10insA
a Normal mean activity of erythrocyte URO-D  4.2 0.6 nmol of coproporphyrinogen/
h/ml packed erythrocytes. Data were obtained at the time of diagnosis; at present, all patients
are on therapy and in remission.
erythrocyte URO-D enzyme activity and on urinary and
plasma porphyrin concentrations (table 3). Seven new
mutations were identified, including four missense mu-
tations: a TrG tranversion in exon 6, at genomic nt
g1663 (cDNA nt 494), which predicted replacement of
a methionine by an arginine at position 165 (a change
designated “M165R”); a CrT transition in exon 6, at
genomic nt g1752 (cDNA nt 583), which predicted sub-
stitution of a leucine by a phenylalanine at residue 195
(a change designated “L195F”); a CrA transversion in
exon 9, at genomic nt g2711 (cDNA nt 912), which
predicted an asparagine-to-lysine substitution of posi-
tion 304 (a change designated “N304K”); and a GrA
transition (at a CpG dinucleotide) of genomic nt g3124
(cDNA nt 995) in exon 10, which predicted an arginine-
to-histidine substitution at residue 332 (a change des-
ignated “R332H”) (table 3).
A novel splicing mutation (designated “E314E”) was
detected as a GrA transition (gDNA nt 2741; cDNA nt
942) of the last base of exon 9 (figs. 2A–2C). In addition,
two gene rearrangements were identified. A single aden-
osine insertion 10 bp downstream from the initiation
ATG in exon 1, at genomic nt g10 (cDNA nt 10; a
change designated “g10insA” fig. 3A) caused a frame-
shift, which resulted in 13 different amino acids and in
a termination signal in codon 17 of exon 2. The second
gene rearrangement was a large deletion of 1,053 bases,
designated “g645D1053”(fig. 3B). When the long-range
PCR product amplified from genomic DNA of the pro-
band was electrophoresed, two amplicons were ob-
served, one the expected ∼3.6-kb band and the other a
smaller, ∼2.6-kb band. Sequencing of the smaller prod-
uct revealed a deletion of 1,053 bases, which included
the region from the fifth base of exon 2 (g645) to g1698
in exon 6. A 10-bp direct repeat (GATCGCCAGA) from
the intron 1/exon 2 junction was inserted at the 5′ break-
point (see fig. 3B). Of note, the insertion mutation was
found in four unrelated families from different areas of
Argentina, whereas each of the other mutations was
identified in only one Argentinean f-PCT family.
Prokaryotic Expression of the URO-D Missense
Mutations
To further characterize the URO-D missense muta-
tions, pK-UROD expression vectors for each of the mu-
tant alleles were constructed and were expressed in E.
coli, and the URO-D activities of the mutant proteins
were determined, as shown in table 4. The activity of
mutation M165R was !2% of the mean level expressed
by the normal allele, whereas the N304K and L195F
alleles expressed mutant polypeptides that had signifi-
cant residual activity (19.5% and 32.1%, respectively,
of the expressed normal mean activity). Interestingly, the
R332H allele expressed more activity (127%) than the
normal allele. However, stability studies indicated that
the R332Hmutant polypeptide was significantly less sta-
ble than the wild-type enzyme when incubated at 37C,
pH 7.0 (fig. 4). Compared with the ∼105-min half-life
of the normal enzyme, the half-life of R332H activity
was ∼40 min, which indicates that the mutant protein
had a markedly reduced stability.
Characterization of Splice-Site Mutation E314E
Sequencing of the URO-D gene in the proband of
family 1 identified a GrA transition in the last base of
exon 9 (change E314E; fig. 2A), which did not alter the
amino acid sequence. To determine whether this exonic
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Figure 2 Characterization of splicing mutation E314E. A, Partial sequencing gel showing E314E due to a GrA transition at g2741, the
last base of exon 9. Also shown are (B) agarose-gel electrophoresis and (C) partial sequencing of the URO-D RT-PCR product amplified from
total lymphoblast RNA from a normal individual and from the f-PCT patient, which shows the deletion of exon 9.
mutation altered the splicing of intron 9, RT-PCR was
performed on total mRNA from the leukocytes of the
proband. Two PCR products were observed; one was of
normal size, and the second was shorter by ∼60–70 bp
(fig. 2B). Sequencing of the RT-PCR products revealed
that the normal-size product had the normal sequence,
whereas the entire 67-bp exon 9 was deleted in the
shorter amplicon and exon 8 was joined directly to exon
10 (fig. 2C)
Haplotype Analysis of the g10insA Alleles
The g10insA microinsertion was identified in four pre-
sumably unrelated PCT families. To determine whether
these f-PCT families were related, haplotype analysiswas
performed with six polymorphic markers that mapped
closely to the URO-D gene at 1p34 (Dib et al. 1996).
Although families 7 and 10 were of Arab and Spanish
descent, respectively, their probands had the same hap-
lotype for all six markers (table 5), which indicates a
common ancestry of their g10insA mutation.
Discussion
The identification and characterization of seven new
mutations in the URO-D gene that cause f-PCT highlight
the molecular heterogeneity underlying this porphyria.
These mutations were detected by amplification of the
entire genomic sequence and by cycle sequencing of the
exons and adjacent intron/exon boundaries in the 3.6-
kb amplicon. Four missense mutations, a coding-region
splicing mutation, the first large deletion, and the first
microinsertion causing f-PCT were identified. Figure 5
shows both the newly identified and all previously pub-
lished URO-D mutations that cause f-PCT. The fact that
the seven mutations reported in the present study were
found in 10 f-PCT families from Argentina attests to the
remarkable genetic heterogeneity underlying this inher-
ited porphyria. That the g10insA mutation occurred in
four Argentinean families suggests a possible common
origin of the mutation. Indeed, haplotyping of poly-
morphic markers flanking the URO-D gene indicate that
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Table 4
Expression of URO-D Mutations in E. coli
Construct
Mean URO-D
Activitya [Range]
(U/mg)
% of Mean
Normal Activity
pK223-3 .14 [.10–.18] 0
pK-UROD 16.4 [9.79–24.7] 100
pK-UROD-M165R .21 [.18–.23] 1.36
pK-UROD-L195F 5.27 [2.60–10.3] 32.1
pK-UROD-N304K 3.21 [1.61–5.07] 19.5
pK-UROD-R332H 20.8 [13.7–27.5] 127.0
a Average of five to eight independent determinations.
Figure 3 A, Partial sequencing gels showing the adenine insertion, g10insA, in exon 2. B, Partial sequencing gel showing the deletion of
1,053 bp, from g645, in exon 2, to g1698, in the middle of exon 6. Note that the deleted region was replaced by a 10-bp direct repeat of the
starred intron 1/exon 2 sequence.
the microinsertion in families 7 and 10, of Arab and
Spanish descent, respectively, shared a common haplo-
type, whereas families 8 and 9, both of Spanish ancestry,
had different haplotypes (table 5). These findings suggest
either that the mutation is very old or, more likely, that
the microinsertion arose independently at least three
times.
Crystallographic studies have indicated that URO-D
is active as a dimeric protein (Whitby et al. 1998), so
that missense mutations can alter enzymatic function,
subunit association, and/or stability of the dimer. Pro-
karyotic expression of the four newly discovered mis-
sense mutations (M165R, L195F, N304K, and R332H)
revealed that each has a unique effect on enzymatic func-
tion. The M165R allele, in which a highly conserved
hydrophobic and neutral methionine is replaced by a
hydrophilic and basic arginine, expressed little, if any,
URO-D activity in E. coli, which indicates that the mu-
tant polypeptide is inactive, unstable, or both. In con-
trast, the other three missense mutations all expressed
enzymatic activity in E. coli, which indicates that these
polypeptides folded such that their active sites retained
at least partial catalytic function. The L195F allele, in
which a hydrophobic and neutral leucine is substituted
by a hydrophobic, neutral, and aromatic phenylalanine
residue, had ∼30% of the mean activity expressed by
the normal allele. Although this leucine has been highly
conserved during evolution, it is notable that phenyl-
alanine is in this position in tobacco and barley URO-
D polypeptides (Swiss-Prot Annotated Protein Sequence
Database trEMBL). Thus, it is not surprising that the
human mutant protein retained significant activity when
expressed in E. coli but that this lesion also rendered
the mutant protein unstable (data not shown).
The N304K mutant allele, in which a neutral aspar-
agine is replaced by a hydrophilic and basic lysine, ex-
pressed an enzyme polypeptide that had ∼20% of nor-
mal activity. This mutation occurred in the middle of a
highly conserved block of seven amino acids that pre-
sumably is important for enzyme function and/or sta-
bility. It is notable that, in E. coli, the R332H allele, in
which a hydrophilic and basic arginine is substituted by
a hydrophilic, basic, and aromatic histidine, expressed
activity that was 1.2-fold greater than normal. However,
the R332H polypeptide was unstable at 37C (fig. 4),
which explains its causative role in f-PCT. It is interesting
to note that only one other URO-D mutation, G318R,
had normal activity and stability when expressed in E.
coli (McManus et al. 1996). However, the frequency of
the G318R lesion in the normal population was not
determined. The fact that the substituted arginine was
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Figure 4 Thermostability of the URO-D activity expressed in E.
coli by pK-UROD and pK-UROD-R332H. Cell extracts were incu-
bated at 37C, pH 7.0, for the times indicated, and the URO-D ac-
tivities were determined. The results are expressed as the percentage
of the initial activity, based on the mean of two independent assays
each for the normal and mutant enzymes.
Table 5
Haplotype Analysis of f-PCT Probands with URO-D Mutation
g10insA
MARKER
(MAP POSITION)a
HAPLOTYPE OF PROBAND INb
Family 8
(Spanish)
Family 10
(Spanish)
Family 7
(Arab)
Family 9
(Spanish)
D1S193 (73.8 cM) 1-1 2-3 2-3 1-1
D1S463 (74.3 cM) 2-4 1-3 1-3 2-3
D1S2713 (74.8 cM) 1-2 3-4 3-4 3-4
D1S211 (75.3 cM) 2-2 2-3 2-2 1-1
D1S2724 (77.4 cM) 2-4 2-3 2-3 1-3
D1S451 (77.6 cM) 2-3 1-2 1-2 1-2
a Markers are those surrounding the chromosomal 1p34 locus of
the URO-D gene. The genetic map position of each polymorphic CA-
repeat marker is measured from the centromere on the short arm of
chromosome 1.
b The order in which the families are listed is based on the relative
identity of their haplotypes; shared haplotypes are underlined for fam-
ilies 7 and 10.
present in this position in a bacterial species suggests
that this mutation may be a rare polymorphism. That
both the G318R and the R332H alleles expressed high
levels of activity in E. coli suggests that the mutations
of these relatively unconserved amino acids are not crit-
ical for catalytic function, although the R332H substi-
tution rendered the polypeptide markedly unstable.
Other enzyme variants, although not expressed at
greater than normal levels, have been shown to have
high to normal activities when expressed in vitro but to
be unstable under physiological conditions, thereby ac-
counting for their pathogenicity (Chen et al. 1994; Xu
et al. 1995; Lai et al 1998). Also, R332H is the only
newly reported mutation that occurred at a CpG di-
nucleotide, a known hot spot for mutations (Cooper and
Youssoufian 1988). Thus, missense mutations that re-
tain some catalytic function would set a higher threshold
for the ecogenic induction of clinical manifestations,
whereas the “out-of-frame” insertion, deletion, and
splicing mutations presumably would render the mutant
mRNA or polypeptide unstable and/or totally inactive.
Another novel exonic point mutation (E314E) resulted
from a GrA transition of the last base in exon 9 and
caused the skipping of exon 9. Although the altered co-
don was degenerate and correctly encoded a glutamic
acid residue, the base substitution changed the 5′ donor
splice site from GAGgtaaca to GAAgtaaca. This nine-
base sequence varied from the 5′ splice-junction consen-
sus sequence, A/CAGgta/ga/gagt. Only 22% of a large
number of recently analyzed mammalian junctions had
an A in the last position of an exon (Krawczak et al.
1992). RT-PCR experiments demonstrated that the ex-
onic GrA substitution prevented normal splicing of the
URO-D mRNA and resulted in the joining of exons 8
and 10. The exon 9 deletion removed 22 amino acids
from the translated polypeptide and altered the down-
stream reading frame. Since this is a major disruption
of the enzyme polypeptide, it is presumed that the mu-
tant protein was catalytically inactive and/or structurally
unstable.
In addition to the point mutations in the URO-D gene,
two gene rearrangements were detected. The g645D1053
mutation deleted ∼30% of the 3.6-kb URO-D gene, in-
cluding most of exon 2 to the middle of exon 6, a region
that encoded 169 of the enzyme’s 367 amino acids. The
10-bp direct repeat flanking the breakpoints suggests
that slipped mispairing or intrachromosomal exchanges
involving short direct repeats was responsible for the
generation of this deletion (Kornreich et al. 1990). The
second gene rearrangement, g10insA, caused a frame-
shift, which altered the amino acids predicted by codons
4–16 (except codons 7, 10, and 11) and created a stop
signal (TGA) in codon 17. This insertion occurred be-
fore, between, or after two adenines, in positions g10
and g11. In the absence of either a longer string of ad-
enines or a flanking direct repeat, it is likely that this
insertion is due to polymerase stutter. Of note, this mu-
tation was detected in four Argentinean families, with
the mutant allele having possibly different ethnic origins.
Haplotyping of the probands with the g10insAmutation
indicated that two of the families were probably related
whereas the other two were not, which suggests that the
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Figure 5 Diagram of the human URO-D gene, showing the rel-
ative location of the mutations causing f-PCT. New mutations de-
scribed here are shown in boldface above the gene.
Table 6
HFE-Gene Mutations C282Y and H63D in Argentinean Patients
with f-PCT
FAMILY
(ANCESTRY)
URO-D
MUTATION
STATUS OF HFE-
GENE MUTATIONa
C282Y H63D
1 (Italian) E314E / /
2 (Portuguese) R332H / /
3 (Spanish) L195F / /
4 (Italian) M165R / /
5 (Spanish) N304K / /
6 (Spanish) g645D1053 ND ND
7 (Arabic) g10insA / /
8 (Spanish) g10insA / /
9 (Spanish) g10insA / /
10 (Spanish) g10insA / /
a A plus sign () denotes presence, and aminus sign () sign denotes
absence; ND  not determined.
insertion mutation is quite old or occurred more than
once. The identification of the g10insAmutation in three
unrelated probands makes it the second most common
mutation in f-PCT, since only a splice-site mutation in
exon 6 has been identified in more (5 of 22) unrelated
families (Garey et al. 1990). Additional studies will be
necessary to determine both the true frequency of this
mutation within the Argentinian population and
whether this mutation is common within any other eth-
nic group.
If the 8 lesions that other investigators (Garey et al.
1989, 1990; Roberts et al. 1995; McManus et al. 1996)
have identified in 11 f-PCT families are taken into ac-
count, a total of 15 URO-D mutations causing f-PCT
now have been recognized. In families with homozygous
dominant HEP, which is much rarer than f-PCT, nine
missense mutations and a large deletion (de Verneuil et
al. 1986a, 1986b, 1988; Romana et al. 1991; de Verneuil
et al. 1992; Meguro et al. 1994; Roberts et al. 1995;
McManus et al. 1996; Moran-Jimenez et al. 1996) have
been identified. Of note, none of the HEP mutations
have been identified in patients with f-PCT, and vice
versa—except for G281E, which was identified in a man
with f-PCT whose nephew had HEP (Roberts et al.
1995). These studies emphasize the underlying genetic
heterogeneity in f-PCT, since most mutations were found
in only one or two families, with the notable exceptions
of the four families with the g10insA lesion and the five
unrelated families with the exon 6 splice-site mutation
(Garey et al. 1990). That some mutant alleles encode
polypeptides with significant residual activity suggests
that patients with these lesions may have either milder
disease or a higher threshold for the induction of disease
manifestations by various ecogenic factors such as iron
overload or alcohol abuse.
To identify possible genotype-phenotype correlations,
the erythrocyte URO-D activities, the plasma and uri-
nary porphyrins, and the clinical records of the affected
individuals from these 10 Argentinean families were re-
viewed. In addition, the presence of the recently iden-
tified common HFE mutations (C282Y and/or H63D),
which cause iron overload, was determined in 9 of the
10 probands. Studies of patients with s-PCT have shown
that, depending on the demographic region, one or the
other of the HFE mutations, C282Y or H63D, is more
frequent in individuals with s-PCT than it is in normal
individuals (Roberts et al. 1997; Sampietro et al. 1998).
In our study, only one patient (i.e., the individual with
the g10insA mutation) was heterozygous for the C282Y
mutation, for an allele frequency of 5.6%, whereas two
patients (i.e., one individual with mutation E313E and
one individual with mutationN304K)were homozygous
and two patients (i.e., one individual with mutation
g10insA and one individual with mutation L195F) were
heterozygous for H63D, for an allele frequency of 33%
(table 6). Thus, the frequency of f-PCT patients with one
or two H63D alleles is four (44%) of nine, whereas only
one of nine (11%) f-PCT patients had a C282Y allele.
Although this is a small sample, the frequency of the
H63D allele in the Argentinean f-PCT patients (33%)
was similar to that in Italian s-PCT patients (28.7%),
whereas the frequency of the C282Y allele in the f-PCT
patients (5.5%) was slightly higher than that found in
Italian s-PCT patients (1.1%). The similarity in the fre-
quencies of these HFE mutations in the normal Argen-
tinean and Italian populations may reflect the fact that
most of the Argentinean f-PCT patients have Iberian or
Italian ancestry. Further studies are needed to determine
the frequency of the HFE mutations in normal individ-
uals from Argentina; however, it is likely that the fre-
quency of the HFE mutations is higher in f-PCT patients
than in normal individuals and, thus, may be an im-
portant factor predisposing to f-PCT manifestations. Al-
though the exact role of the H63D mutation in causing
iron overload is less clear than that of the C282Y mu-
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tation, the Italian study suggests that theH63Dmutation
may cause a subtle iron-metabolism abnormality that
results in hepatocellular accumulation of toxic iron spe-
cies, thereby predisposing toward or precipitating the
clinical manifestations of s-PCT (Sampietro et al. 1998).
It is interesting to note that the proband with the
splice-site mutation, who is homozygous for the H63D
mutation, had severe PCT clinical manifestations and
that these began at the age of 5 years (A. M. de C. Batlle,
unpublished data). The other patient homozygous for
H63D had a point mutation in her URO-D gene and
had milder PCT manifestations. However, overall, no
clear genotype-phenotype correlations between the dif-
ferent URO-D mutations, clinical symptoms, and pres-
ence or absence of HFE mutations was observed in these
Argentinean patients, which suggests that other impor-
tant factors contribute to the onset, frequency, and se-
verity of the clinical manifestations in PCT. Moreover,
once the diagnosis is established, the institution of ef-
fective therapy by chronic phlebotomies and/or chlo-
roquine obfuscates such correlations. In summary, the
identification and characterization of these seven new
mutations in the URO-D gene that cause f-PCT highlight
the molecular heterogeneity underlying f-PCT, permit
the precise diagnosis of asymptomatic heterozygotes in
these Argentinean families, and provide the information
for future structure-function studies of the human
enzyme.
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